If you have relapsed Chronic Lymphocytic Leukemia (#CLL), you can help forward medical research by participating in an important new clinical trial to test if adding an investigational medication (ublituximab) to ibrutinib (Imbruvica®), an FDA-approved treatment, improves outcomes for CLL patients with high-risk disease.
If you are interested, the full study details and eligibility criteria are listed here.
More about the study:
• The investigational drug is administered by infusion and the FDA approved drug ibrutinib is administered by oral capsules • This is a phase 3 trial • There will be approximately 330 participants in this trial
You or a loved one may be able to take part in this trial if you: • Are at least 18 years old; • Have been diagnosed with and received prior treatment for CLL; • Have relapsed CLL that now requires additional treatment; and • Have at least one high-risk genetic abnormality (your doctor or the study staff can help you determine if you have a high-risk abnormality).
Matching participants to trials is a critical problem facing CLL research. Can you help find new treatments for patients with relapsed CLL?
Please complete the online questionnaire to check if you’re eligible for the trial.
If you’re not familiar with clinical trials, here are some FAQs:
What are clinical trials?
Clinical trials are research studies to determine whether investigational drugs or treatments are safe and effective for humans. All new investigational medications and devices must undergo several clinical trials, often involving thousands of people.
Why participate in a clinical trial?
You may have access to new investigational treatments that would be available to the general public only upon approval. You will also receive study-related medical care and attention from clinical trial staff at research facilities. Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.